Long‐term follow‐up of impulse control disorders in Parkinson's disease
Identifieur interne : 002781 ( Main/Exploration ); précédent : 002780; suivant : 002782Long‐term follow‐up of impulse control disorders in Parkinson's disease
Auteurs : Eugenia Mamikonyan [États-Unis] ; Andrew D. Siderowf [États-Unis] ; John E. Duda [États-Unis] ; Marc N. Potenza [États-Unis] ; Stacy Horn [États-Unis] ; Matthew B. Stern [États-Unis] ; Daniel Weintraub [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2008-01.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Antiparkinson Agents (therapeutic use), Dopamine agonist, Drug Administration Schedule, Female, Follow-Up Studies, Gambling (psychology), Humans, Impulse Control Disorders (diagnosis), Impulse Control Disorders (epidemiology), Impulse control disorder, Interview, Psychological, Long term, Male, Middle Aged, Nervous system diseases, Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Parkinson Disease (psychology), Parkinson disease, Parkinson's disease, Severity of Illness Index, Time Factors, dopamine agonist, gambling, impulse control disorders.
- MESH :
- chemical , therapeutic use : Antiparkinson Agents.
- diagnosis : Impulse Control Disorders.
- drug therapy : Parkinson Disease.
- epidemiology : Impulse Control Disorders, Parkinson Disease.
- psychology : Gambling, Parkinson Disease.
- Drug Administration Schedule, Female, Follow-Up Studies, Humans, Interview, Psychological, Male, Middle Aged, Severity of Illness Index, Time Factors.
Abstract
Recent studies have linked dopamine agonist (DA) usage with the development of impulse control disorders (ICDs) in Parkinson's disease (PD). Little is known about optimal management strategies or the long‐term outcomes of affected patients. To report on the clinical interventions and long‐term outcomes of PD patients who developed an ICD after DA initiation. Subjects contacted by telephone for a follow‐up interview after a mean time period of 29.2 months. They were administered a modified Minnesota Impulse Disorder Interview for compulsive buying, gambling, and sexuality, and also self‐rated changes in their ICD symptomatology. Baseline and follow‐up dopamine replacement therapy use was recorded and verified by chart review. Of 18 subjects, 15 (83.3%) participated in the follow‐up interview. At follow‐up, patients were receiving a significantly lower DA levodopa equivalent daily dosage (LEDD) (Z = −3.1, P = 0.002) and a higher daily levodopa dosage (Z = −1.9, P = 0.05), but a similar total LEDD dosage (Z = −0.47, P = 0.64) with no changes in Unified Parkinson's Disease Rating Scale motor score (Z = −1.3, P = 0.19). As part of ICD management, 12 (80.0%) patients discontinued or significantly decreased DA treatment, all of whom experienced full or partial remission of ICD symptoms by self‐report, and 10 (83.3%) of whom no longer met diagnostic criteria for an ICD. For PD patients who develop an ICD in the context of DA treatment, discontinuing or significantly decreasing DA exposure, even when offset by an increase in levodopa treatment, is associated with remission of or significant reduction in ICD behaviors without worsening in motor symptoms. © 2007 Movement Disorder Society
Url:
- https://api.istex.fr/document/1B72CC1DB29E2C297DA19D27283EF395DC37F5E1/fulltext/pdf
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2651355
DOI: 10.1002/mds.21770
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001727
- to stream Istex, to step Curation: 001727
- to stream Istex, to step Checkpoint: 001337
- to stream Pmc, to step Corpus: 000017
- to stream Pmc, to step Curation: 000017
- to stream Pmc, to step Checkpoint: 000443
- to stream PubMed, to step Corpus: 002492
- to stream PubMed, to step Curation: 002492
- to stream PubMed, to step Checkpoint: 002233
- to stream Ncbi, to step Merge: 001E67
- to stream Ncbi, to step Curation: 001E67
- to stream Ncbi, to step Checkpoint: 001E67
- to stream Main, to step Merge: 003359
- to stream PascalFrancis, to step Corpus: 001414
- to stream PascalFrancis, to step Curation: 001905
- to stream PascalFrancis, to step Checkpoint: 001206
- to stream Main, to step Merge: 003814
- to stream Main, to step Curation: 002781
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term follow‐up of impulse control disorders in Parkinson's disease</title>
<author><name sortKey="Mamikonyan, Eugenia" sort="Mamikonyan, Eugenia" uniqKey="Mamikonyan E" first="Eugenia" last="Mamikonyan">Eugenia Mamikonyan</name>
</author>
<author><name sortKey="Siderowf, Andrew D" sort="Siderowf, Andrew D" uniqKey="Siderowf A" first="Andrew D." last="Siderowf">Andrew D. Siderowf</name>
</author>
<author><name sortKey="Duda, John E" sort="Duda, John E" uniqKey="Duda J" first="John E." last="Duda">John E. Duda</name>
</author>
<author><name sortKey="Potenza, Marc N" sort="Potenza, Marc N" uniqKey="Potenza M" first="Marc N." last="Potenza">Marc N. Potenza</name>
</author>
<author><name sortKey="Horn, Stacy" sort="Horn, Stacy" uniqKey="Horn S" first="Stacy" last="Horn">Stacy Horn</name>
</author>
<author><name sortKey="Stern, Matthew B" sort="Stern, Matthew B" uniqKey="Stern M" first="Matthew B." last="Stern">Matthew B. Stern</name>
</author>
<author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:1B72CC1DB29E2C297DA19D27283EF395DC37F5E1</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1002/mds.21770</idno>
<idno type="url">https://api.istex.fr/document/1B72CC1DB29E2C297DA19D27283EF395DC37F5E1/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001727</idno>
<idno type="wicri:Area/Istex/Curation">001727</idno>
<idno type="wicri:Area/Istex/Checkpoint">001337</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Mamikonyan E:long:term:follow</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2651355</idno>
<idno type="RBID">PMC:2651355</idno>
<idno type="wicri:Area/Pmc/Corpus">000017</idno>
<idno type="wicri:Area/Pmc/Curation">000017</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000443</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">002492</idno>
<idno type="wicri:Area/PubMed/Curation">002492</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002233</idno>
<idno type="wicri:Area/Ncbi/Merge">001E67</idno>
<idno type="wicri:Area/Ncbi/Curation">001E67</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001E67</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Mamikonyan E:long:term:follow</idno>
<idno type="wicri:Area/Main/Merge">003359</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:08-0115899</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001414</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001905</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001206</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Mamikonyan E:long:term:follow</idno>
<idno type="wicri:Area/Main/Merge">003814</idno>
<idno type="wicri:Area/Main/Curation">002781</idno>
<idno type="wicri:Area/Main/Exploration">002781</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term follow‐up of impulse control disorders in Parkinson's disease</title>
<author><name sortKey="Mamikonyan, Eugenia" sort="Mamikonyan, Eugenia" uniqKey="Mamikonyan E" first="Eugenia" last="Mamikonyan">Eugenia Mamikonyan</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Department of Psychiatry, University of Pennsylvania, Philadelphia</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Siderowf, Andrew D" sort="Siderowf, Andrew D" uniqKey="Siderowf A" first="Andrew D." last="Siderowf">Andrew D. Siderowf</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Department of Neurology, University of Pennsylvania, Philadelphia</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Parkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Duda, John E" sort="Duda, John E" uniqKey="Duda J" first="John E." last="Duda">John E. Duda</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Department of Neurology, University of Pennsylvania, Philadelphia</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Parkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Potenza, Marc N" sort="Potenza, Marc N" uniqKey="Potenza M" first="Marc N." last="Potenza">Marc N. Potenza</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Connecticut</region>
</placeName>
<wicri:cityArea>Department of Psychiatry, Yale University, New Haven</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Connecticut</region>
</placeName>
<wicri:cityArea>Mental Illness Research, Education and Clinical Center (MIRECC), West Haven Veterans Affairs Medical Center, West Haven</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Horn, Stacy" sort="Horn, Stacy" uniqKey="Horn S" first="Stacy" last="Horn">Stacy Horn</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Department of Neurology, University of Pennsylvania, Philadelphia</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Stern, Matthew B" sort="Stern, Matthew B" uniqKey="Stern M" first="Matthew B." last="Stern">Matthew B. Stern</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Department of Neurology, University of Pennsylvania, Philadelphia</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Parkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Department of Psychiatry, University of Pennsylvania, Philadelphia</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Department of Neurology, University of Pennsylvania, Philadelphia</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Parkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Mental Illness Research, Education and Clinical Center (MIRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia</wicri:cityArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2008-01">2008-01</date>
<biblScope unit="vol">23</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="75">75</biblScope>
<biblScope unit="page" to="80">80</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">1B72CC1DB29E2C297DA19D27283EF395DC37F5E1</idno>
<idno type="DOI">10.1002/mds.21770</idno>
<idno type="ArticleID">MDS21770</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (therapeutic use)</term>
<term>Dopamine agonist</term>
<term>Drug Administration Schedule</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Gambling (psychology)</term>
<term>Humans</term>
<term>Impulse Control Disorders (diagnosis)</term>
<term>Impulse Control Disorders (epidemiology)</term>
<term>Impulse control disorder</term>
<term>Interview, Psychological</term>
<term>Long term</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (epidemiology)</term>
<term>Parkinson Disease (psychology)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Severity of Illness Index</term>
<term>Time Factors</term>
<term>dopamine agonist</term>
<term>gambling</term>
<term>impulse control disorders</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Impulse Control Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Impulse Control Disorders</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Gambling</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Drug Administration Schedule</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Interview, Psychological</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Severity of Illness Index</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Long terme</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du système nerveux</term>
<term>Stimulant dopaminergique</term>
<term>Trouble du contrôle des impulsions</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Recent studies have linked dopamine agonist (DA) usage with the development of impulse control disorders (ICDs) in Parkinson's disease (PD). Little is known about optimal management strategies or the long‐term outcomes of affected patients. To report on the clinical interventions and long‐term outcomes of PD patients who developed an ICD after DA initiation. Subjects contacted by telephone for a follow‐up interview after a mean time period of 29.2 months. They were administered a modified Minnesota Impulse Disorder Interview for compulsive buying, gambling, and sexuality, and also self‐rated changes in their ICD symptomatology. Baseline and follow‐up dopamine replacement therapy use was recorded and verified by chart review. Of 18 subjects, 15 (83.3%) participated in the follow‐up interview. At follow‐up, patients were receiving a significantly lower DA levodopa equivalent daily dosage (LEDD) (Z = −3.1, P = 0.002) and a higher daily levodopa dosage (Z = −1.9, P = 0.05), but a similar total LEDD dosage (Z = −0.47, P = 0.64) with no changes in Unified Parkinson's Disease Rating Scale motor score (Z = −1.3, P = 0.19). As part of ICD management, 12 (80.0%) patients discontinued or significantly decreased DA treatment, all of whom experienced full or partial remission of ICD symptoms by self‐report, and 10 (83.3%) of whom no longer met diagnostic criteria for an ICD. For PD patients who develop an ICD in the context of DA treatment, discontinuing or significantly decreasing DA exposure, even when offset by an increase in levodopa treatment, is associated with remission of or significant reduction in ICD behaviors without worsening in motor symptoms. © 2007 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Connecticut</li>
<li>Pennsylvanie</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Mamikonyan, Eugenia" sort="Mamikonyan, Eugenia" uniqKey="Mamikonyan E" first="Eugenia" last="Mamikonyan">Eugenia Mamikonyan</name>
</region>
<name sortKey="Duda, John E" sort="Duda, John E" uniqKey="Duda J" first="John E." last="Duda">John E. Duda</name>
<name sortKey="Duda, John E" sort="Duda, John E" uniqKey="Duda J" first="John E." last="Duda">John E. Duda</name>
<name sortKey="Horn, Stacy" sort="Horn, Stacy" uniqKey="Horn S" first="Stacy" last="Horn">Stacy Horn</name>
<name sortKey="Potenza, Marc N" sort="Potenza, Marc N" uniqKey="Potenza M" first="Marc N." last="Potenza">Marc N. Potenza</name>
<name sortKey="Potenza, Marc N" sort="Potenza, Marc N" uniqKey="Potenza M" first="Marc N." last="Potenza">Marc N. Potenza</name>
<name sortKey="Siderowf, Andrew D" sort="Siderowf, Andrew D" uniqKey="Siderowf A" first="Andrew D." last="Siderowf">Andrew D. Siderowf</name>
<name sortKey="Siderowf, Andrew D" sort="Siderowf, Andrew D" uniqKey="Siderowf A" first="Andrew D." last="Siderowf">Andrew D. Siderowf</name>
<name sortKey="Stern, Matthew B" sort="Stern, Matthew B" uniqKey="Stern M" first="Matthew B." last="Stern">Matthew B. Stern</name>
<name sortKey="Stern, Matthew B" sort="Stern, Matthew B" uniqKey="Stern M" first="Matthew B." last="Stern">Matthew B. Stern</name>
<name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
<name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
<name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
<name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002781 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002781 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:1B72CC1DB29E2C297DA19D27283EF395DC37F5E1 |texte= Long‐term follow‐up of impulse control disorders in Parkinson's disease }}
This area was generated with Dilib version V0.6.23. |